Procter & Gamble stock steadies near $145 as fiscal 2026 results meet guidance
Published on 09/01/2026 at 07:59 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Procter & Gamble Co. (ISIN US7427181091) stock is holding in the mid-$140 range as investors digest fiscal 2026 results that delivered steady growth while a major restructuring program and modest core EPS guidance frame expectations for fiscal 2027 as of August 30, 2026.
Recent market data as of August 30, 2026, 4:00 p.m. ET shows the shares closing at $143.71 on the NYSE, with a consensus price target of $161.19 implying a discount of $17.48, which represents more than 12 percent below the average analyst valuation.
For investors, the current picture combines fiscal 2026 revenue of $87 billion, net profit of $16.1 billion, and operating cash flow of $19.6 billion with an ongoing restructuring program that is expected to cost between $1 billion and $1.6 billion pretax over roughly two years and trim organic growth by 0.3 to 0.5 percentage points in fiscal 2027.
Fiscal 2026 numbers and restructuring impact
Procter & Gamble reported that its fiscal year ended June 2026 generated sales of $87 billion, representing revenue growth of 3 percent compared with the prior fiscal year, according to recent earnings commentary.
Within that fiscal 2026 performance, the company recorded net profit of $16.1 billion and operating cash flow of $19.6 billion, underlining a strong cash generation profile that supports ongoing dividends and investment despite restructuring costs.
The restructuring program, which includes workforce reductions and changes to the product line, carries an estimated total pretax cost in a range between $1 billion and $1.6 billion over approximately two years, with more than half of the anticipated costs already recorded by July 2026.
Company projections indicate that the removal of selected brands, formats, and marketing approaches could reduce organic growth in fiscal 2027 by between 0.3 and 0.5 percentage points, illustrating how the restructuring acts as a measurable drag on near-term top-line expansion even as it aims to streamline operations.
In the nine months ended March 2026, Procter & Gamble had already booked $455 million in restructuring-related expenses associated with employee departures, showing that the program is materially affecting current-period results rather than being solely a long-term plan.
Guidance and consensus for fiscal 2027
Looking ahead, Procter & Gamble has set its fiscal 2027 core EPS guidance in a range from $6.89 to $7.11 per share, which corresponds to expected core EPS that is unchanged to up 3 percent compared with fiscal 2026.
Equities analysts currently expect core earnings per share of $6.98 for the ongoing fiscal year, placing the consensus projection close to the midpoint of management’s guidance range and reinforcing the idea that the market anticipates modest, rather than rapid, profit growth.
One recently cited estimate lowered the forecast for fiscal 2027 EPS to $6.98 from a prior projection of $7.00, aligning the bank’s view with the broader consensus while still pointing to incremental growth compared with the fiscal 2026 baseline.
In addition to forward-looking EPS figures, the stock’s valuation multiples remain elevated relative to some consumer-staples peers, with one overview noting that Procter & Gamble trades at more than 20 times forward 12-month earnings versus lower multiples for comparable companies in the household and personal products space.
Despite this richer valuation, analyst data compiled in late August 2026 indicates that the shares carry an average rating of Moderate Buy and an average price target of $161.19, suggesting that the consensus still sees upside from the current $143.71 level as of August 30, 2026.
Go deeper
Recent valuation and guidance context
For a detailed look at how fiscal 2026 results, restructuring charges, and fiscal 2027 guidance interact with valuation and consensus expectations, investors can review the latest Procter & Gamble earnings and outlook articles on leading market-data portals.
Oral care brands anchor the portfolio
Beyond the numbers, one representative Procter & Gamble product line that matters for long-term growth is its oral care business built around the Oral-B and related brands, which includes manual and electric toothbrushes, toothpaste, and oral hygiene accessories sold worldwide.
These oral care products occupy a premium positioning in many markets, often featuring technology-driven enhancements such as connected electric toothbrushes and specialized brush heads, which help the company maintain pricing power and defend market share against lower-priced competitors.
As restructuring reshapes Procter & Gamble’s overall portfolio, maintaining strong, innovation-led franchises like oral care is likely to be critical for supporting the company’s ability to deliver the modest core EPS growth targeted in fiscal 2027 while sustaining dividend payments and cash returns to shareholders.
Shares trade below consensus valuation
As of August 30, 2026, 4:00 p.m. ET, Procter & Gamble stock closed at $143.71 on the NYSE, placing it below the $161.19 consensus price target by $17.48, a gap that translates into a discount of more than 12 percent relative to the average analyst valuation.
At that share price and based on an annual dividend of $4.35 per share that was highlighted in recent dividend announcements, the implied dividend yield stands close to 3 percent, offering income-focused investors a combination of cash returns and moderate expected earnings growth.
Fact box
Company: Procter & Gamble Co.
ISIN: US7427181091
Ticker: PG
Exchange: NYSE
Price (as of August 30, 2026, 4:00 p.m. ET): $143.71 USD
Market cap: $170 billion (as of August 30, 2026)
Sector / Industry: Consumer staples / Household and personal products
Index membership: S&P 500
